Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ENC-201
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Khosla Ventures
Deal Size : $9.9 million
Deal Type : Financing
Details : The financing will advance a Phase 1 clinical trial evaluating subcutaneous transplantation of primary islets within Encellin’s encapsulated cell replacement therapy, ENC-201, in Type 1 Diabetes (T1D).
Product Name : ENC-201
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : ENC-201
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Khosla Ventures
Deal Size : $9.9 million
Deal Type : Financing